[Unicocell] Application for Clinical Trial Design Change for ELIXCYTE
Unicocell announced on May 29, 2026, that it has applied to the Ministry of Health and Welfare to change the design of its Phase 3 clinical trial for the knee osteoarthritis drug ELIXCYTE. The change aims to add an interim analysis to obtain key efficacy data earlier. Enrollment was completed in November 2025.
📋 Article Processing Timeline
- 📰 Published: May 29, 2026 at 09:00
- 🔍 Collected: May 30, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 31, 2026 at 18:30 (34h 30m after Collected)
1. Date of event: 2026/05/29
2. Drug name: ELIXCYTE
3. Purpose: Treatment of knee osteoarthritis
4. Expected stages: Phase 3 clinical trial and new drug registration.
5. Current stage: (1) Received approval for Phase 3 on Feb 8, 2023, and completed enrollment on Nov 12, 2025. Applied for design change to include interim analysis. (2) Risk management: N/A. (3) Future direction: N/A. (4) Accumulated R&D expenses: Not disclosed to protect international licensing negotiations.
6. Next stage: Will be adjusted based on progress.
7. Market status: According to WHO, 528 million people suffer from osteoarthritis globally. The market is expected to reach 15.3 billion USD by 2034. There is a high unmet medical need for long-term effective drug treatments.
2. Drug name: ELIXCYTE
3. Purpose: Treatment of knee osteoarthritis
4. Expected stages: Phase 3 clinical trial and new drug registration.
5. Current stage: (1) Received approval for Phase 3 on Feb 8, 2023, and completed enrollment on Nov 12, 2025. Applied for design change to include interim analysis. (2) Risk management: N/A. (3) Future direction: N/A. (4) Accumulated R&D expenses: Not disclosed to protect international licensing negotiations.
6. Next stage: Will be adjusted based on progress.
7. Market status: According to WHO, 528 million people suffer from osteoarthritis globally. The market is expected to reach 15.3 billion USD by 2034. There is a high unmet medical need for long-term effective drug treatments.
FAQ
What is the status of the ELIXCYTE clinical trial by Unicocell?
Phase 3 enrollment is complete, and they are applying for a change in trial design.